HCPS

CenSyn and HonorHealth announce strategic partnership

Retrieved on: 
Thursday, December 15, 2022
Titan, Seizure, Rehabilitation, HCPS, Rapids, Diagnosis, Partnership, Stroke, Patient, Concussion, Neuro, Neurosurgery, Neurology, Brain, Berkeley SkyDeck, Health, Organization, Medical imaging, Medical device, Hospital

SCOTTSDALE, Ariz., Dec. 15, 2022 /PRNewswire/ -- CenSyn, a digital telehealth company advancing portable screening of brain health-related conditions via its platform for integrated brain health screening, is pleased to announce its strategic partnership with HonorHealth, a leading healthcare system serving 1.6 million people in the greater Phoenix area.

Key Points: 
  • CenSyn and HonorHealth are pleased to announce a strategic partnership to collaborate on CenSyn's Pre-FDA medical platform for on-the-go screening of seizure, concussion and long-term brain health-related disorders.
  • SCOTTSDALE, Ariz., Dec. 15, 2022 /PRNewswire/ -- CenSyn, a digital telehealth company advancing portable screening of brain health-related conditions via its platform for integrated brain health screening, is pleased to announce its strategic partnership with HonorHealth, a leading healthcare system serving 1.6 million people in the greater Phoenix area.
  • CenSyn will conduct future clinical studies with HonorHealth clinicians to deliver breakthrough approaches to patients in brain health evaluation management.
  • CenSyn is headquartered inScottsdale, Arizona, with funding support from HonorHealth, Sunstone Management, Doctors for Health Innovation (D4HI), Berkeley SkyDeck, Titan Angels, and others.

Verana Health Study of Patients with Dry Age-Related Macular Degeneration Reveals Compelling New Insights Published in International Ophthalmology Journal

Retrieved on: 
Thursday, December 15, 2022
Visual acuity, Physician, EHR, Geographic atrophy, Severe cognitive impairment, HCPS, Data management, HCP, GA, Varnaq, AMD, American Academy, American Academy of Ophthalmology, Macular degeneration, Patient, Vance DeGeneres, American Academy of Neurology, Research, Disease, IRIS, Medicine, Health, Stanford University School of Medicine, Quality of life, Risk, Multimedia, American Urological Association, RWD, SAN, Machine Intelligence Research Institute, Pharmaceutical industry, Publishing, Medical imaging, Therapy, Ophthalmology

SAN FRANCISCO, Dec. 15, 2022 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has published the results of a study Verana Health conducted to analyze American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) data for insights into characterizing the most common form of vision loss in the elderly population, age-related macular degeneration (AMD). The study, "Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry," is a novel study to report on how the stage of disease, as determined by visual acuity (VA), can help predict the risk of progression in dry AMD (dAMD) by stage.

Key Points: 
  • Macular degeneration occurs when a person's retina becomes damaged over time, leading to different levels of vision loss.
  • The study used curated real-world data (RWD) from the Academy IRIS Registrymanaged by Verana Health's VeraQ population health data engineto better understand how patients progress through the stages of dAMD.
  • To request a copy ofthe recently published study, conducted by Dr. Leng and a team of researchers from Verana Health, visit: veranahealth.com/amd-manuscript .
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

HearUSA to Carry Sony's Over-the-Counter Hearing Aids, Accelerating Its Commitment to Bring the "Sound of the New Age" to Millions of New Clients

Retrieved on: 
Thursday, December 15, 2022
Sony, Music, OTC, HCPS, Food, Life, New Age, Sound, Electronics, PALM, WS Audiology, Research, Kool-Aid, Sony Corporation of America, Hearing loss, Robotics, Doctor of Audiology, Film, Engineering, Food and Drug Administration, Hearing, Marketing, Dentistry

PALM BEACH GARDENS, Fla., Dec. 15, 2022 /PRNewswire/ -- Responding to the Food and Drug Administration's recent approval of over-the-counter (OTC) hearing aids, today HearUSA announced that it will offer Sony's new over-the-counter hearing aids. The first two models – the Sony CRE-C10 and Sony CRE-E10 – will be available for clients to purchase early next year in all HearUSA centers and online. 

Key Points: 
  • Further, as a strong consumer brand, Sony will help shatter the stigma associated with hearing loss and guide more people towards better hearing health.
  • "Sixty-five percent of the people in the United States with hearing loss do not wear hearing aids.
  • [1] OTC hearing aids will help raise awareness about hearing health and engage more clients with an effective solution to start on the journey to better hearing health sooner one to be guided by our hearing care professionals."
  • HearUSA has developed a guided process to help clients discover whether they are a good candidate for OTC hearing aids based on their type and severity of hearing loss.

Amalgam Rx Named to the 2022 CB Insights’ Digital Health 150 List

Retrieved on: 
Wednesday, December 7, 2022
Nanotechnology, Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Data Management, Stem Cells, Science, Technology, Practice Management, Clinical Trials, FDA, Biotechnology, Diabetes, Health, CB Insights, Self-management, EHR, Digital technology, HCPS, Medical device, R, HCP, AR, Workflow, Amalgam, Patient, Research, Laika (EHR testing framework), Digital, SVP, History, Multimedia, Digital health, CB, Algorithm, Organization, Cryptocurrency, Medicine, Retail, Medical imaging, Mosaic

CB Insights today named Amalgam Rx to its fourth-annual Digital Health 150 , showcasing the 150 most promising private digital health companies of 2022.

Key Points: 
  • CB Insights today named Amalgam Rx to its fourth-annual Digital Health 150 , showcasing the 150 most promising private digital health companies of 2022.
  • View the full release here: https://www.businesswire.com/news/home/20221207005487/en/
    Amalgam Rx Named to the 2022 CB Insights Digital Health 150 List (Photo: Business Wire)
    "From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this years Digital Health 150 winners are transforming the future of healthcare with digital technology, said Brian Lee, SVP of CB Insights Intelligence Unit.
  • Utilizing the CB Insights platform , the research team selected these 150 winners from a pool of over 13,000 private companies, including applicants and nominees.
  • Quick facts on the 2022 Digital Health 150:
    Equity funding and deals: Since 2017, this year's Digital Health 150 winners have raised around $5.6B in equity funding across 378 deals.

ENA by Zayo Brings Relief To K-12 School Districts With New Offerings

Retrieved on: 
Wednesday, December 7, 2022
Mobile, Wireless, Technology, Security, Telecommunications, Software, Networks, Internet, Data Management, Primary, Secondary, Education, Hillsborough County Public Schools, ENA, Ageing, Alexander Forbes Group Holdings, Private, NPS, IP, School, Zayo Group, LTE, Risk, Face, Digital, Wi-Fi, Workforce, HCPS, Student, Network address, Acquisition, Renewable energy, Mobile phone, Computer security

With ENA Ally, K-12 school districts can now leverage specialized technical expertise to optimize their network infrastructure and technology systems with ease.

Key Points: 
  • With ENA Ally, K-12 school districts can now leverage specialized technical expertise to optimize their network infrastructure and technology systems with ease.
  • The ENA Ally technology services will address the numerous challenges school districts face today, including:
    Workforce Shortages and Hiring Challenges: School districts are in crisis management mode and are scrambling to fill a rapidly increasing number of vacancies.
  • As a part of ENA by Zayos commitment to delivering exceptional customer care, the ENA Ally services are tailored to meet individual school districts' needs.
  • With the acquisition of ENA, Zayo connects over 19,000 K-12 schools around the U.S.
    To learn more about ENA by Zayos ENA Ally Technology Services, please visit https://www.ena.com/solutions/technology-services/ena-ally/ .

98% of Pharmaceutical Executives Agree on Importance of Omnichannel as Half of Companies Are Not Optimizing Physician Engagement across Touchpoints, Study Finds

Retrieved on: 
Tuesday, December 6, 2022
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Trailblazer, Physician, ROI, HCPS, Novartis, HCP, Health, Novo Nordisk, Data, AI, News, GSK, Merck, DHC, Omnichannel, Sanofi, Organization, Risk management, Pharma

Today, its a strategic imperative for brands to transform the HCP experience into a seamless, cross-channel journey thats personalized to a segment of one.

Key Points: 
  • Today, its a strategic imperative for brands to transform the HCP experience into a seamless, cross-channel journey thats personalized to a segment of one.
  • More than half of the world's top-20 pharmaceutical companies including Novartis, GSK, Novo Nordisk, Merck, Sanofi, and Pfizer rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs.
  • For a complete copy of the DHC Group study and to understand organizational readiness for omnichannel, please contact Lisa Barbadora ( [email protected] ) or click here .
  • Connect with Aktana on LinkedIn: linkedin.com/company/aktana
    Aktana is the category creator and leader of intelligent engagement in the global life sciences industry.

Verana Health and the American Academy of Ophthalmology Launch the Verana Research Network, an IRIS Registry Initiative

Retrieved on: 
Wednesday, December 7, 2022
Physician, HCPS, Data management, HCP, American Academy of Ophthalmology, American Academy, Partnership, VTC, Health, Patient, American Academy of Neurology, IRIS, Medicine, Academic health science centre, Quality of life, Surgeon, Clinical trial, American Urological Association, AMCS, SAN, RWE, Confederation of Laboratories for Artificial Intelligence Research in Europe, Medical imaging, Pharmaceutical industry, MD, Ophthalmology

SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Verana Health® and the American Academy of Ophthalmology (Academy) today announced the Verana Research Network, an IRIS® Registry (Intelligent Research in Sight) initiative intended to help advance data-driven clinical research and care.

Key Points: 
  • Partnership seeks to increase clinical trials access, accelerate recruitment, and advance ophthalmic research
    SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Verana Health and the American Academy of Ophthalmology (Academy) today announced the Verana Research Network, an IRIS Registry (Intelligent Research in Sight) initiative intended to help advance data-driven clinical research and care.
  • The Verana Research Network includes ten founding sites and is now inviting additional practices across the IRIS Registry to participate.
  • "With the Verana Research Network, the Academy and Verana Health are helping clinical trial sites run data-driven trials that can potentially bring therapeutic innovations to patients faster."
  • "The Verana Research Networkand our partnership with the American Academy of Ophthalmologyis helping advance ophthalmic research and accelerate treatments for patients."

UPDATE: Cornerstone Specialty Network Hosts a Successful Community Oncology Focused Data Review Meeting: October 2022

Retrieved on: 
Thursday, December 1, 2022
Health, European Society for Medical Oncology, Oncology, Research, Mayo Clinic, Community Oncology Alliance, Symposia, HCPS, ESMO, Medicine, MD, HOPE

The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.

Key Points: 
  • The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.
  • In addition to the ESMO Data Review Meeting, Cornerstone Specialty Network also hosts the following data review meetings:
    Cornerstone Oncology Fellowship Advancement Initiative (COFAI) - Specifically customized for oncologists who are new to the community setting with the goal of accelerating quality patient care.
  • To view any of the data review meetings, please visit https://www.cornerstoneoncology.com/events/
    Cornerstone Specialty Network, LLC is the leading provider of long-term, sustainable value through an aggregated network of Community Oncology practices.
  • Through network aggregation, Cornerstone Specialty Network delivers value-added opportunities that support independence and long-term sustainability for community oncology practices.

PharmaForce International: Benchmarking Report Captures the Digital Marketing Trends of Key Oncology and Immunology Companies

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Small Business Saturday, Digital, Multimedia, HCPS, Social media, Patient, Keylor Navas, PFI, Oncology, Immunology, Intelligence, Benchmarking, ROI, Online shopping

READING, Pa., Dec. 1, 2022 /PRNewswire/ -- PharmaForce International (PFI) recently published a benchmarking report covering the digital marketing trends and expenditures of key Oncology and Immunology companies.

Key Points: 
  • READING, Pa., Dec. 1, 2022 /PRNewswire/ -- PharmaForce International (PFI) recently published a benchmarking report covering the digital marketing trends and expenditures of key Oncology and Immunology companies.
  • The report provides a strategic overview of the best practices, as well as each individual company's approach to the evolving digital marketing landscape.
  • One trend, in particular, is the progression of the digital marketing footprint over the past 20 years.
  • Now, companies have gone back to utilizing some face-to-face interactions, but still dedicate a much larger percentage of marketing approaches to digital methods.

Cornerstone Specialty Network Hosts a Successful Community Oncology Focused Data Review Meeting: October 2022

Retrieved on: 
Thursday, December 1, 2022
Research, HCPS, Community Oncology Alliance, Health, Oncology, ESMO, European Society for Medical Oncology, Symposia, Mayo Clinic, Medicine, HOPE, MD

The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.

Key Points: 
  • The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.
  • In addition to the ESMO Data Review Meeting, Cornerstone Specialty Network also hosts the following data review meetings:
    Cornerstone Oncology Fellowship Advancement Initiative (COFAI) - Specifically customized for oncologists who are new to the community setting with the goal of accelerating quality patient care.
  • To view any of the data review meetings, please visit https://www.cornerstoneoncology.com/events/
    Cornerstone Specialty Network, LLC is the leading provider of long-term, sustainable value through an aggregated network of Community Oncology practices.
  • Through network aggregation, Cornerstone Specialty Network delivers value-added opportunities that support independence and long-term sustainability for community oncology practices.